key: cord-0904719-4rcu78vx
authors: Guan, Minhui; Johannesen, Eric; Tang, Cynthia Y; Hsu, Albert L; Barnes, Courtney L; Burnam, Megan; McElroy, Jane A; Wan, Xiu-Feng
title: Intrauterine fetal demise in the third trimester of pregnancy associated with mild infection with the SARS-CoV-2 Delta variant without protection from vaccination
date: 2022-01-13
journal: J Infect Dis
DOI: 10.1093/infdis/jiac007
sha: e4655d42fd41986c012848aa35114c801fef1dde
doc_id: 904719
cord_uid: 4rcu78vx

SARS-CoV-2 has a higher infection rate in pregnant women than age-matched adults. With increased infectivity and transmissibility, the Delta variant is predominant worldwide. Here, we describe intrauterine fetal demise in an unvaccinated women with mild symptoms of SARS-CoV-2 Delta variant infection. Histology and elevated proinflammatory responses of the placenta suggest that fetal demise was associated with placental malperfusion due to Delta variant infection. This study suggests that the Delta variant can cause severe morbidity and mortality to fetuses. Vaccination should continve to be advocated and will likely continue to reduce SARS-CoV-2 infection risks for pregnant women and their fetuses.

A c c e p t e d M a n u s c r i p t

The COVID-19 pandemic has been caused by the SARS-CoV-2 virus and has led to >266 million cases wordwide, of which ~5.26 million have been fatal as of 8 December, 2021. Pregnant women are particularly vulnerable to COVID-19 and have a 70% higher infection rate than agematched adults [1] . Between January 22, 2020 and December 6, 2021, a total of 150,036 pregnant women were confirmed with COVID-19 infections in the United States (US) alone. A PCR positivity rate of 15.4% with SARS-CoV-2 was reported in women presenting in labor in New York City, regardless of symptoms [2] . Pregnant women with COVID-19 typically experience mild illness, and their births are often uncomplicated [3] . However, there have been reports of pregnancy complications like pre-eclampsia, preterm birth, intrauterine fetal demise (IUFD), and stillbirth, as well as serious maternal illness which required intensive care, and even maternal death [4] . The recent Morbidity and Mortality Weekly Report on November 19, 2021 indicated that a COVID-19 diagnosis during the delivery hospitalization was associated with an increased risk for stillbirth in the US, with a stronger association when the Delta variant was predominant [5] .

SARS-CoV-2 has evolved rapidly and novel genetic variants continue to emerge and challenge disease prevention and control. The Delta variant has become the predominant variant worldwide, with a prevalence of 98.8% in the US as of Aug 24, 2021. The Delta variant has been reported to be more contagious and some individuals still have breakthrough infections despite vaccination [6, 7] . A large-scale cohort study showed patients with the Delta variant had more risk of hospital admission compared to patients with the Alpha variant, indicating that the Delta variant in unvaccinated populations may lead to higher healthcare burdens [8] . In this study, we describe IUFD associated with placental malperfusion due to cytokine storm during the third trimester of a pregnancy complicated by mild Delta infection.

Ethics approval and biosafety. This study has been approved by the University of Missouri institutional review board (IRB #2063342 and #2025449) and proper consent was obtained. All work A c c e p t e d M a n u s c r i p t with live SARS-CoV-2 was performed in a BSL-3 laboratory in compliance with state and federal regulations and with the approval of the University of Missouri Institutional Biosafety Committee.

Placental Immunohistochemistry (IHC) antigen staining. Sections of placenta were deparaffinized, rehydrated, and underwent antigen retrieval and endogenous peroxidase activity quenching, then blocked with 10% normal goat serum before incubation with SARS-CoV-2 spike-specific mouse monoclonal antibody (Invitrogen, Carlsbad, CA). Sections were treated with a biotinylated goat antimouse IgG polyclonal secondary antibody, and ABC reagent (Vector lab, Burlingame, CA) was applied following the manufacturer's instructions. Sections were counterstained with hematoxylin, washed, dehydrated, and covered with coverslip. A c c e p t e d M a n u s c r i p t 1μl of cDNA. The parameters of the qPCR were as follows: one cycle at 50°C for 2 minutes, one cycle at 95°C for 2 minutes, followed by 40 cycles at 95°C for 1 second and 60°C for 30 seconds. The relative mean fold changes for genes of interest are normalized with house keeping genes (Supplementary Table 1 ).

Micro-neutralization assay. Sera were heat-inactivated for 60 minutes at 56°C. The DMEM high glucose supplemented with 2% FBS and Antibiotic-Antimycotic was used as diluent. Two-fold serial dilutions of the serum, starting from 1:10, were mixed with an equal volume of virus with 100 TCID 50 of SARS-CoV-2. The serum-virus mixture was incubated for 1 hour at 37°C. After incubation, Vero E6 cells was added into each well. The cytopathogenic effect was observed for neutralization titers after a 72-hour incubation at 37°C with 5% CO 2 .

A 25-year-old pregnant multigravida at 27+5 weeks gestation age, with diet-controlled gestational diabetes and a body mass index of 17, presented to the emergency department (ED) with mild COVID-19 symptoms, including 103ºF fever, scratchy throat, and cough. The patient was diagnosed with SARS-CoV-2 infection, with reassuring fetal monitoringin the ED. Three days after diagnosis, the patient presented with vaginal bleeding and decreased fetal movement, went into active labor, and delivered a demised male infant vaginally. The patient's postpartum course was complicated by disseminated intravascular coagulation, and she was discharged home after two days of hospitalization.

As per routine IUFD evaluation, patient was IgM negative but IgG positive against parvovirus B19 and cytomegalovirus. She was immune to rubella and negative for toxoplasma. IHC was negative in placenta for cytomegalovirus and herpes simplex virus. Her urine toxicology screen was negative for controlled substances. The fetus did not display any gross anomalies. Fetal chromosomal microarray confirmed a normal male with no clinically relevant copy number changes or loss of 

The placenta is a physical and immunological barrier against fetal infection. Viral infection of the placenta triggers immune responses at the maternal-fetal interface. A cytokine storm at the placenta may trigger placental malperfusion and even abruption, and the intravasal coagulation at the utero-placental level can cause IUFD. The human placenta expresses receptors of SARS-CoV-2 and proteases that trigger viral fusion [10] . Pregnant women infected with SARS-CoV-2 during the first and third trimesters may have higher risks of inducing exaggerated responses causing a cytokine storm [11] . In the third trimester IUFD present in this study, our data suggests that the excessive infiltration of immune cells and cytokine storm at the placenta due to the Delta variant caused severe placental inflammation and damage, which likely resulted in placental abruption and the demise of the fetus. The limitation of our study is that we did not have access to control placental tissue from a A c c e p t e d M a n u s c r i p t gestational age-matched pregnant individual with gestational diabetes, but no SARS-CoV-2 infection for comparison of the pathological and cytokine expression levels. Thus, our comparison was to a normal placenta. However, a previous study reported no significant differences in the expression of TNF-α, IL-6, IL-8, and several other genes of interest in the placentas of women with gestational diabetes mellitus relative to those of healthy pregnant women [12] , whereas we found TNF-α and IL-8 were significantly elevated in our COVID-19 patient.

Studies showed that symptomatic pregnant women with COVID-19 are at increased risk for severe COVID-19 associated illness compared to non-pregnant women [1, 13] . During the third trimester, SARS-CoV-2-positive women were shown to have more maternal and fetal vascular malperfusion, villous agglutination, and subchorionic thrombi [14] . The presence of SARS-CoV-2 infection in placenta has also been reported in COVID-19 patients [3] . Among these cases of placental infections, one mother experienced a complicated second trimester pregnancy with preeclampsia and placental abruption, one had mild COVID-19 symptoms with a normal, healthy birth, and one experienced moderate symptoms while the neonate also contracted COVID-19 and suffered from neurological manifestations. However, IUFD associated with maternal SARS-CoV-2 infections have been generally rare, and all of these cases were associated with severe maternal complications [15] [16] [17] . The maternal characteristics and symptoms included overweight or obese individuals experiencing mild to moderate COVID-19 symptoms. Additionally, different extents of placental inflammation were reported, such as inflammation and fibrin deposition in and between the villi [15] , chorionitis, infarction, and necrosis of the placental parenchyma [16] and mixed inflammatory infiltrates in the subchorial space [17] . There is also evidence of minimal to no placental changes in some diabetic women compared to control groups [18] .

This report adds to the literatures a case of IUFD in a pregnant woman caused by Delta variant. Evidence suggests that risk for stillbirth was significantly higher during the period of Delta predominance than during the pre-Delta period [5] . The rapid fetal demise indicates that close fetal monitoring of infected pregnant women, regardless of symptom severity, should be considered.

COVID-19 vaccines are widely accepted to be safe and stimulate robust antibody responses in pregnant women [19] [20] [21] [22] [23] . However, among pregnant women, there is only 24% vaccine coverage of individuals with at least 1 dose in the US as of November 27, 2021. The rise of the Delta variant coupled with high vaccine hesitancy in pregnant women raises public health concerns regarding the potential for greater disease severity and worse outcomes, as observed in the unvaccinated patient discussed in this case. Evidence shows that the COVID-19 vaccine has high levels of effectiveness against symptomatic disease with the Delta variant after full vaccination [6, 24] .Thus, vaccination should continue to be strongly advocated and will likely continue to reduce SARS-CoV-2 infection risks for pregnant women and their fetuses. 

Higher severe acute respiratory syndrome coronavirus 2 infection rate in pregnant patients

Universal screening for SARS-CoV-2 in pregnant women admitted for delivery: how to manage antibody testing?

Placental SARS-CoV-2 in a pregnant woman with mild COVID-19 disease

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization -United States

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Covid-19 Vaccine Effectiveness in New York State

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. The Lancet Infectious Diseases

Neutralizing antibody titres in SARS-CoV-2 infections

Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia

SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review

Expression of adipokines and estrogen receptors in adipose tissue and placenta of patients with gestational diabetes mellitus

Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study

Third-trimester placentas of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive women: histomorphology, including viral immunohistochemistry and in-situ hybridization

Fetal deaths in pregnancies with SARS-CoV-2 infection in Brazil: A case series

Placental pathology and fetal demise at 35 weeks of gestation in a woman with SARS-CoV-2 infection: A case report

Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection

Placenta changes in pregnancy with gestational diabetes

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women

Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21

Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion

Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

We thank Rebecca Patterson, George Sarafianos, Naser Ashiekh, and Jess Bottger for their efforts in sample collection and Dr. Yang Wang for designing primers for sequencing. We appreciate routine assistance in the lab from Liping Long, Olivia Jacobson, and Haley Hudson. We are grateful for the facility and technical support from Jeffery Adamovicz, Travis McCarthy, and Paul Anderson at University of Missouri-Columbia.

A c c e p t e d M a n u s c r i p t